USSTOCK.TODAY
Market Closed
Log in Sign up

SeaStar Medical Holding Corp. Reports Surge in QUELIMMUNE Revenue and Breakthrough Device Designation

The Motley Fool +1 · ·by G4L

ICU
ICU SeaStar Medical Holding Corp
$1.92 +1.05%
View chart & analysis →
  1. 1SeaStar Medical recorded a 247% year-over-year increase in net revenue for the third quarter of 2026.
  2. 275% of the 339 subjects for SeaStar Medical's NEUTRALIZE-AKI pivotal clinical trial have been enrolled.
  3. 3SeaStar Medical Holding Corp. announced a breakthrough device designation for adult sepsis.

So what's the key point?

SeaStar Medical Holding Corp. revenue increased significantly by 247% compared to last year. The company has established a foundation for growth following its designation as a new medical device.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Alpha Cognition Revenue Increases in Q3 2026 Amid Accelerated Commercial Growth of ZUNVEYL The Motley Fool +1 · 13m agoA2Z Cust2Mate Solutions Corp. Records $10.9 Million in Q3 Revenue The Motley Fool +1 · 13m agoDoubleDown Interactive Q3 Adjusted EBITDA Up 7.2% and Tender Offer Approved The Motley Fool +1 · 13m ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news